Valuation: Gilead Sciences, Inc.

Market Cap 179B 159B 149B 136B 256B 17,253B 258B 1,801B 698B 8,820B 674B 659B 28,307B P/E 2026 *
-43.8x
P/E 2027 * 18x
Enterprise Value 196B 174B 163B 148B 280B 18,863B 282B 1,969B 763B 9,643B 737B 721B 30,948B EV / Sales 2026 *
6.39x
EV / Sales 2027 * 5.77x
Free-Float
99.88%
Yield 2026 *
2.27%
Yield 2027 * 2.31%
Oct. 02 Legend Biotech Faces Pressure From Rivals Ahead of Key FDA Decision, UBS Says MT
Sep. 28 Mirum's liver infection drug lowers virus levels in late-stage study RE
Sep. 25 HEALTH ROUNDS-Genetic discovery yields clues toward reversal of Alzheimer's brain damage RE
Sep. 23 Hackensack Meridian Center for Discovery and Innovation, Gilead Sciences and the Rockefeller University Collaborate to Research Oral Treatments for Mosquito-Borne Flaviviruses CI
Sep. 18 Dr. Reddy's Confirms License for Gilead's Yearly-Once HIV Drug; Shares Up 2% MT
Sep. 16 Gilead Sciences Insider Sold Shares Worth $432,646, According to a Recent SEC Filing MT
Sep. 16 Gilead Sciences, Inc. Expands Royalty-Free Voluntary Licensing Agreements For Lenacapavir With Dr. Reddy?s Laboratories Limited, Emcure Pharmaceuticals Limited, Eva Pharma For Pharmaceutical Industries S.A.E., Ferozsons Laboratories Limited, Hetero And Mylan Laboratories Limited CI
Sep. 16 Gilead Sciences Expands Licensing Agreements for HIV Treatment MT
Sep. 15 Gilead Sciences, Inc. and Pan American Health Organization Announce Milestone Partnership to Accelerate Access to Twice-Yearly Lenacapavir for HIV Prevention Across Latin America and the Caribbean CI
Sep. 15 Gilead Sciences, Inc. Presents at Morgan Stanley 24th Annual Global Healthcare Conference, Sep-15-2026 10:45 AM
Sep. 15 Gilead Sciences Expands Lenacapavir Access to 14 Countries MT
Sep. 15 Gilead, PAHO agree on HIV prevention drug access in Latin America, Caribbean RE
Sep. 10 Gilead Sciences, Inc. Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference, Sep-10-2026 10:55 AM
1 day-1.87%
1 week-4.10%
Current month-2.89%
1 month-3.26%
3 months+10.26%
6 months+3.60%
Current year+17.92%
1 week 144
Extreme 144
152.74
1 month 142.94
Extreme 142.94
154.2
Current year 116.88
Extreme 116.88
157.29
1 year 112.41
Extreme 112.41
157.29
3 years 62.07
Extreme 62.07
157.29
5 years 57.16
Extreme 57.165
157.29
10 years 56.56
Extreme 56.56
157.29
Manager TitleAgeSince
Chief Executive Officer 61 2019-02-28
Director of Finance/CFO 56 2019-10-31
Compliance Officer - 2025-12-17
Director TitleAgeSince
Director/Board Member 58 2016-08-18
Director/Board Member 73 2017-12-31
Director/Board Member 72 2018-05-08
Date Insider Type Main position Quantity % Market Cap. Importance
9/22/26 Exercice

Controller/Auditor

5,214 0.0004%
9/15/26 Sell

Executive/Senior Manager

-3,000 0.0002%
9/15/26 Sell

Chief Financial Officer

-3,000 0.0002%
Change 5-day change 1-year change 3-year change Capi.($)
-1.87%-4.10%+30.92%+95.33% 179B
-0.61%-3.43%+39.40%+112.31% 1,019B
-1.02%-5.60%+37.67%+65.02% 617B
+1.11%-0.58%+11.10%+77.28% 464B
+0.34%-3.01%+61.21%+40.71% 356B
-0.95%-4.05%+21.60%+39.37% 333B
-1.46%-2.89%+11.84%+24.60% 267B
-1.35%-5.43%-4.69%+8.40% 244B
-1.04%-2.79%+35.52%+51.34% 218B
-0.50%-1.68%-32.98%-60.94% 166B
Average -0.26%-3.22%+21.16%+45.34% 386.29B
Weighted average by Cap. +0.38%-3.25%+27.79%+63.38%

Financials

2026 *2027 *
Net sales 30.7B 27.28B 25.46B 23.21B 43.77B 2,951B 44.17B 308B 119B 1,509B 115B 113B 4,842B 32.68B 29.04B 27.1B 24.7B 46.59B 3,142B 47.02B 328B 127B 1,606B 123B 120B 5,155B
Net income -4.27B -3.8B -3.54B -3.23B -6.09B -411B -6.15B -42.9B -16.62B -210B -16.05B -15.7B -674B 10.28B 9.13B 8.52B 7.77B 14.65B 988B 14.78B 103B 39.96B 505B 38.58B 37.74B 1,621B
Net Debt 16.75B 14.88B 13.89B 12.66B 23.87B 1,610B 24.09B 168B 65.12B 823B 62.87B 61.51B 2,641B 9.12B 8.11B 7.57B 6.9B 13.01B 877B 13.13B 91.57B 35.48B 448B 34.26B 33.51B 1,439B
Logo Gilead Sciences, Inc.
Gilead Sciences, Inc. specializes in the development, manufacturing and marketing of therapeutic products. Net sales break down by source of income as follows: - sale of drugs (98.2%): for the treatment of HIV (71.8% of net sales), oncology diseases (11.2%), hepatitis B virus (11.1%), Ebola virus (3.2%) and other (2.7%; primarily cytomegalovirus retinitis, and advanced Kaposi sarcoma resulting from HIV); - other (1.8%): especially royalties and revenue from research and development services and from subcontracted production of therapeutic products. Net sales are distributed geographically as follows: the United States (70.9%), Europe (17.2%) and other (11.9%).
Employees
17,000
Date Price Change Volume
26-10-02 $144.74 -1.87% 5,044,221
26-10-01 $147.50 -1.04% 4,438,698
26-09-30 $149.05 -1.47% 5,357,405
26-09-29 $151.28 -0.61% 5,322,556
26-09-28 $152.21 +0.85% 5,081,993
Trader
Investor
Global
Quality
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
27
Last Close Price
144.74USD
Average target price
158.65USD
Spread / Average Target
+9.61%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. GILD Stock